Haemonetics (HAE) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $127.42 +5.94%
Revenue Growth %: +5.6%
Financial Fact:
Net income: 0.39
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +5.6%
Financial Fact:
Net income: 0.39
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $0.83, $0.15 better than the analyst estimate of $0.68. Revenue for the quarter came in at $297.48 million versus the consensus estimate of $270.46 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mueller Water Products, Inc. (MWA) Reports In-Line Q4 EPS; Offers Guidance
- Universal Corp. (UVV) Misses Q2 EPS by 83c
- DHI Group (DHX) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
